U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO Complete if Known Application Number 10/618,084 INFORMATION DISCLOSURE July 14, 2003 Filing Date STATEMENT BY APPLICANT First Named Inventor Donald J. ZACK Art Unit (Use as many sheets as necessary) Examiner Name Attorney Docket Number of 1 001107.00370

NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of T² the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue Cite Examiner No.1 number(s), publisher, city and/or country-where-published. Initials * PRESTA, L.G. et el., "Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders," Cancer Research, (15 Oct. 1997), Vol. 57, No. 20, pp. 4593-4599 SCHENK, D. et al., "Immunization with amyloid-b attenuates Alzheimer-disease-like pathology in the PDAPP mouse," Nature, (08 Jul. 1999), Vol. 400, pp. 173-177 KRENZ, N.R. et al., "Neutralizing Intraspinal Nerve Growth Factor Blocks Automatic Dysreflexia Caused by Spinal Cord Injury," J. Neuroscience (01 Sept. 1999), Vol. 19, No. 17, pp. 7405-7414 BROSAMLE, C. et al., "Regeneration of Lesioned Corticospinal Tract Fibers in the Adult Rat Induced by a Recombinant, Humanized IN-1 Antibody Fragment," J. Neuroscience, (01 Nov. 2000), Vol. 20, No. 21, pp. 8061-MEAD et al., "Evaluation of Anti-TGF-b2 Antibody as a New Posteperative Apti-Scarning Agent in Glaucoma Surgery," Investigative Opthalmology & Visual Science, (August 2003), Vol. 44, No. 8, pp. 3394-3401

Examiner Date Considered 450

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.